Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance

References

• Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014; 50:1330-44; PMID:24650579; http://dx.doi.org/10.1016/j.ejca.2014.01.029
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88:921-32; PMID:10679663; http://dx.doi.org/10.1002/(SICI)1097-0142(20000215)88:4<921::AID-CNCR24>3.0.CO;2-S
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97; PMID:20728210; http://dx.doi.org/10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Cunningham D, Okines AF, Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2010; 362:858-9; PMID:20200397; http://dx.doi.org/10.1056/NEJMc0911925
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46; PMID:18172173; http://dx.doi.org/10.1056/NEJMoa073149
   PubMed Web of Science ®Google Scholar
• Huang S, Chen M, Shen Y, Shen W, Guo H, Gao Q, Zou X. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 2012; 315:198-205; PMID:22104727; http://dx.doi.org/10.1016/j.canlet.2011.10.011
   PubMed Web of Science ®Google Scholar
• Chen J, Ding Z, Peng Y, Pan F, Li J, Zou L, Zhang Y, Liang H. HIF-1alpha inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLoS One 2014; 9:e98882; PMID: 24901645; http://dx.doi.org/10.1371/journal.pone.0098882
   PubMed Web of Science ®Google Scholar
• Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62:3387-94; PMID:12067980
   PubMed Web of Science ®Google Scholar
• Breier A, Gibalova L, Seres M, Barancik M, Sulova Z. New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem 2013; 13:159-70; PMID:22931413; http://dx.doi.org/10.2174/187152013804487380
   PubMed Web of Science ®Google Scholar
• Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One 2009; 4:e6819; PMID:19714248; http://dx.doi.org/10.1371/journal.pone.0006819
   PubMed Web of Science ®Google Scholar
• Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, Michiels C, Sacchi A, Onisto M, D'Orazi G. Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta 2009; 1793:368-77; PMID:19046997; http://dx.doi.org/10.1016/j.bbamcr.2008.10.013
   PubMed Web of Science ®Google Scholar
• Nardinocchi L, Puca R, Sacchi A, D'Orazi G. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer 2009; 8:1; PMID:19128456; http://dx.doi.org/10.1186/1476-4598-8-1
   PubMed Web of Science ®Google Scholar
• Gisel A, Valvano M, El Idrissi IG, Nardulli P, Azzariti A, Carrieri A, Contino M, Colabufo NA. miRNAs for the detection of multidrug resistance: overview and perspectives. Molecules 2014; 19:5611-23; PMID:24786846; http://dx.doi.org/10.3390/molecules19055611
   PubMed Web of Science ®Google Scholar
• Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer 2010; 126:2-10; PMID:19634138; http://dx.doi.org/10.1002/ijc.24782
   PubMed Web of Science ®Google Scholar
• Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, Pogribny IP. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7:2152-9; PMID:18645025; http://dx.doi.org/10.1158/1535-7163.MCT-08-0021
   PubMed Web of Science ®Google Scholar
• Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, Azzariti A, Aprile G, Delcuratolo S, Signorile M, et al. Micro-RNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget 2015; 15:6(27):23323-41; PMID:26259238; http://dx.doi.org/10.18632/oncotarget.4492
   Web of Science ®Google Scholar
• Pinto R, Strippoli S, De Summa S, Albano A, Azzariti A, Guida G, Popescu O, Lorusso V, Guida M, Tommasi S. MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. Expert Opin Ther Targets 2015:1-9; PMID:26156293; http://dx.doi.org/10.1517/14728222.2015.1065818
   PubMedGoogle Scholar
• Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol 2010; 119:125-30; PMID:20624637; http://dx.doi.org/10.1016/j.ygyno.2010.06.004
   PubMed Web of Science ®Google Scholar
• Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu T, Hu T, Li J. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/beta-catenin pathway in hepatocellular carcinoma cells. Cell Signal 2013; 25:2693-701; PMID:24018051; http://dx.doi.org/10.1016/j.cellsig.2013.08.032
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76:582-8; PMID:18619946; http://dx.doi.org/10.1016/j.bcp.2008.06.007
   PubMed Web of Science ®Google Scholar
• Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, Sidransky D, Ratovitski E. Phospho-DeltaNp63alpha is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ 2011; 18:1220-30; PMID:21274007; http://dx.doi.org/10.1038/cdd.2010.188
   PubMed Web of Science ®Google Scholar
• Nallamshetty S, Chan SY, Loscalzo J. Hypoxia: a master regulator of microRNA biogenesis and activity. Free Radic Biol Med 2013; 64:20-30; PMID:23712003; http://dx.doi.org/10.1016/j.freeradbiomed.2013.05.022
   PubMed Web of Science ®Google Scholar
• Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 2011; 44:839-47; PMID:21605702; http://dx.doi.org/10.1016/j.jbi.2011.05.002
   PubMed Web of Science ®Google Scholar
• Xu K, Liang X, Shen K, Cui D, Zheng Y, Xu J, Fan Z, Qiu Y, Li Q, Ni L, et al. miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Biochem J 2012; 446:291-300; PMID:22676135; http://dx.doi.org/10.1042/BJ20120386
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013; 587:3069-75; PMID:23932924; http://dx.doi.org/10.1016/j.febslet.2013.06.058
   PubMed Web of Science ®Google Scholar
• Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 2014; 33:3267-76; PMID:23893241; http://dx.doi.org/10.1038/onc.2013.297
   PubMed Web of Science ®Google Scholar
• Wang F, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 2013; 434:688-94; PMID:23603256; http://dx.doi.org/10.1016/j.bbrc.2013.04.010
   PubMed Web of Science ®Google Scholar
• Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li F, Chen G, Zhou J, Wang S, Xu G, et al. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J Cancer Res Clin Oncol 2010; 136:447-56; PMID:19760195; http://dx.doi.org/10.1007/s00432-009-0675-4
   PubMed Web of Science ®Google Scholar
• Wartenberg M, Ling FC, Muschen M, Klein F, Acker H, Gassmann M, Petrat K, Putz V, Hescheler J, Sauer H. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. FASEB J 2003; 17:503-5; PMID:12514119; http://dx.doi.org/10.1096/fj.02-0358fje
   PubMed Web of Science ®Google Scholar
• He Q, Zhang G, Hou D, Leng A, Xu M, Peng J, Liu T. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep 2011; 25:237-43; PMID:21109982; http://dx.doi.org/10.3892/or_00001066
   PubMed Web of Science ®Google Scholar
• Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011; 15:2164-75; PMID:21070600; http://dx.doi.org/10.1111/j.1582-4934.2010.01213.x
   PubMed Web of Science ®Google Scholar
• Toscano-Garibay JD, Aquino-Jarquin G. Regulation exerted by miRNAs in the promoter and UTR sequences: MDR1/P-gp expression as a particular case. DNA Cell Biol 2012; 31:1358-64; PMID:22662865; http://dx.doi.org/10.1089/dna.2012.1703
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011; 30:55; PMID:21569481; http://dx.doi.org/10.1186/1756-9966-30-55
   PubMed Web of Science ®Google Scholar
• Puca R, Nardinocchi L, Givol D, D'Orazi G. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene 2010; 29:4378-87; PMID:20514025; http://dx.doi.org/10.1038/onc.2010.183
   PubMed Web of Science ®Google Scholar
• Saul VV, de la Vega L, Milanovic M, Kruger M, Braun T, Fritz-Wolf K, Becker K, Schmitz ML. HIPK2 kinase activity depends on cis-autophosphorylation of its activation loop. J Mol Cell Biol 2013; 5:27-38; PMID:23000554; http://dx.doi.org/10.1093/jmcb/mjs053
   PubMed Web of Science ®Google Scholar
• Siepi F, Gatti V, Camerini S, Crescenzi M, Soddu S. HIPK2 catalytic activity and subcellular localization are regulated by activation-loop Y354 autophosphorylation. Biochim Biophys Acta 2013; 1833:1443-53; PMID:23485397; http://dx.doi.org/10.1016/j.bbamcr.2013.02.018
   PubMed Web of Science ®Google Scholar
• Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S, Fusco A. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 2007; 117:693-702; PMID:17290307; http://dx.doi.org/10.1172/JCI29852
   PubMed Web of Science ®Google Scholar
• Polonio-Vallon T, Kirkpatrick J, Krijgsveld J, Hofmann TG. Src kinase modulates the apoptotic p53 pathway by altering HIPK2 localization. Cell Cycle 2014; 13:115-25; PMID:24196445; http://dx.doi.org/10.4161/cc.26857
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Mangia A, Caldarola L, Dell'Endice S, Scarpi E, Saragoni L, Monti M, Santini D, Brunetti O, Simone G, Silvestris N. The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. Cancer Biol Ther 2015; 16:1140-7; PMID:26126066; http://dx.doi.org/10.1080/15384047.2015.1056414
   PubMed Web of Science ®Google Scholar